Endocyte, Inc.
(NASDAQ : ECYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -2.15%152.860.7%$1193.05m
PFEPfizer Inc. -0.16%34.340.9%$1183.43m
MRKMerck & Co., Inc. -1.56%72.160.7%$851.01m
BMYBristol-Myers Squibb Co. -2.03%59.521.0%$795.69m
ABBVAbbVie, Inc. -0.78%105.881.9%$740.30m
LLYEli Lilly & Co. -0.78%200.421.1%$642.23m
AZNAstraZeneca Plc -0.46%46.951.2%$494.96m
GSKGlaxoSmithKline Plc -0.35%34.120.2%$282.66m
NVSNovartis AG -1.02%83.320.2%$165.42m
SNYSanofi 0.37%45.630.2%$156.73m
VTRSViatris, Inc. -3.06%13.460.0%$147.23m
VERUVeru, Inc. -8.44%12.040.0%$100.15m
NVONovo Nordisk A/S -2.98%69.330.1%$84.61m
KALVKalVista Pharmaceuticals, Inc. -3.60%31.030.4%$80.73m
RPRXRoyalty Pharma Plc -3.70%41.960.2%$79.81m

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.